

COPY OF PAPERS
ORIGINAL FILED
ED

RECEIVED

MAR - 7 2002

TECH CENTER 1600/2900

Sheet 1 of 2

Form 1449*

Atty. Docket No.: 600.491US

Serial No. 09/825,765

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Applicant: Yumi Yokoyama et al.

Filing Date: April 4, 2001

Group: 1645

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
STH	5,767,071	06/16/1998	Palladino et al.	514	11	06/07/95
STH	5,792,845	08/11/1998	O'Reilly et al.	536	23.1	10/20/94
STH	5,854,205	12/29/1998	O'Reilly et al.	514	2	10/22/96

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
STH	0896003	02/10/1999	European	C07K	14/75	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
STH	Arap, W., et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model", <u>Science</u> , 279, pp. 377-380, (Jan. 16, 1998)
STH	Boehm, T., et al., "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance", <u>Nature</u> , 390, pp. 404-407, (Nov. 27, 1997)
STH	Brooks, P.C., et al., "Insulin-like Growth Factor Receptor Cooperates With Integrin alphaVbeta5 to promote Tumor Cell Dissemination In Vivo", <u>Journal of Clinical Investigation</u> , 99 (6), pp. 1390-1398, (March 1997)
STH	Dawson, D.W., et al., "Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis", <u>Science</u> , 285, pp. 245-248, (July 9, 1999)
STH	Dhanabal, M., et al., "Endostatin Induces Endothelial Cell Apoptosis", <u>The Journal of Biological Chemistry</u> , 274 (17), pp. 11721-11726, (1999)
STH	Ferrara, N., et al., "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins", <u>Endocrine Reviews</u> , 13 (1), pp. 18-32, (1992)
STH	Folkman, J., "Angiogenesis Inhibitors Generated by Tumors", <u>Molecular Medicine</u> , pp. 120-122, (1995)
STH	Folkman, J., "What is the Evidence That Tumors Are Angiogenesis Dependent?", <u>Journal of the National Cancer Institute</u> , 82 (1), pp. 4-6, (Jan. 3, 1990)
STH	Friedlander, M., et al., "Definition of Two Angiogenic Pathways by Distinct alphaV Integrins", <u>Science</u> , 270, pp. 1500-1502, (Dec. 1, 1995)
STH	Kandel, J., et al., "Neovascularization is Associated with a Switch to the Export of bFGF in the Multistep Development of Fibrosarcoma", <u>Cell</u> , 66, pp. 1095-1104, (Sept. 20, 1991)

Examiner


AShuff

Date Considered

7/18/03

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Sheet 2 of 2

Form 1449*	Atty. Docket No.: 600.491US2	Serial No. 09/825,765
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Yumi Yokoyama et al.	
	Filing Date: April 4, 2001	Group: 1645

OTHER DOCUMENTS

**Examiner
Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

SJM	O'Reilly, M.S., et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin", <u>Science</u> , <u>285</u> , pp. 1926-1928, (Sept. 17, 1999)
SJM	O'Reilly, M.S., et al., "Endostatin: An Endogenous Inhibitor of Antiogenesis and Tumor Growth", <u>Cell</u> , <u>88</u> , pp. 277-285, (Jan. 24, 1997)
SJM	Yokoyama, Y., et al., "Genetic Modification of Human Endostatin: RGD-Motif Potentiates Anti-Tumor Activity", <u>Proceedings of the American Association for Cancer Research</u> , <u>41</u> , Abstract No. 3112, p. 488, (March 2000)

RECEIVED
MAR - 7 2002
TECH CENTER 1600/2900

Examiner <i>Shuff</i>	Date Considered <i>7/18/03</i>
-----------------------	--------------------------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.